O	0	10	Evaluation
O	11	13	of
O	14	19	Short
O	19	20	-
O	20	24	Term
O	25	28	Use
O	29	31	of
B-intervention	32	33	N
I-intervention	33	34	-
I-intervention	34	48	Acetylcysteine
O	49	51	as
O	52	53	a
O	54	62	Strategy
O	63	66	for
O	67	77	Prevention
O	78	80	of
B-condition	81	94	Anthracycline
I-condition	94	95	-
I-condition	95	102	Induced
I-condition	103	117	Cardiomyopathy
O	117	118	:
O	119	124	EPOCH
O	125	130	Trial
O	131	132	-
O	133	134	A
O	135	146	Prospective
O	147	157	Randomized
O	158	163	Study
O	163	164	.

O	165	167	We
O	168	179	investigate
O	180	182	to
O	183	192	determine
O	193	200	whether
O	201	202	N
O	202	203	-
O	203	217	acetylcysteine
O	218	219	(
O	219	222	NAC
O	222	223	)
O	224	227	can
O	228	235	prevent
O	236	249	anthracycline
O	249	250	-
O	250	257	induced
O	258	272	cardiotoxicity
O	272	273	.

O	274	275	A
O	276	281	total
O	282	284	of
B-total-participants	285	288	103
O	289	297	patients
O	298	302	were
O	303	311	enrolled
O	312	314	in
O	315	319	this
O	320	331	prospective
O	332	342	randomized
O	343	347	open
O	348	353	label
O	354	364	controlled
O	365	370	trial
O	370	371	.

O	372	376	They
O	377	380	are
B-eligibility	381	389	patients
I-eligibility	390	395	first
I-eligibility	396	405	diagnosed
I-eligibility	406	410	with
I-eligibility	411	417	breast
I-eligibility	418	424	cancer
I-eligibility	425	427	or
I-eligibility	428	436	lymphoma
I-eligibility	436	437	,
I-eligibility	438	441	who
I-eligibility	442	449	require
I-eligibility	450	462	chemotherapy
I-eligibility	462	463	,
I-eligibility	464	473	including
I-eligibility	474	487	anthracycline
I-eligibility	488	492	like
I-eligibility	493	504	adriamycine
I-eligibility	505	507	or
I-eligibility	508	519	epirubicine
O	519	520	.

O	521	529	Patients
O	530	534	were
O	535	545	randomized
O	546	548	to
O	549	552	the
O	553	556	NAC
O	557	562	group
O	563	564	{
O	564	565	n
O	565	566	=
B-intervention-participants	566	568	50
O	568	569	;
O	570	574	1200
O	575	577	mg
O	578	584	orally
O	585	590	every
O	591	592	8
O	593	598	hours
O	599	607	starting
O	608	614	before
O	615	618	and
O	619	625	ending
O	626	631	after
O	632	635	the
O	636	647	intravenous
O	648	656	infusion
O	657	659	of
O	660	673	anthracycline
O	674	676	in
O	677	680	all
O	681	693	chemotherapy
O	694	700	cycles
O	701	702	(
O	702	703	3
O	703	704	-
O	704	705	6
O	705	706	)
O	706	707	}
O	708	710	or
O	711	714	the
B-control	715	722	control
I-control	723	728	group
O	729	730	(
O	730	731	n
O	731	732	=
B-control-participants	732	734	53
O	734	735	)
O	735	736	.

O	737	744	Primary
O	745	752	outcome
O	753	756	was
O	757	760	the
B-outcome-Measure	761	769	decrease
I-outcome-Measure	770	772	in
I-outcome-Measure	773	777	left
I-outcome-Measure	778	789	ventricular
I-outcome-Measure	790	798	ejection
I-outcome-Measure	799	807	fraction
I-outcome-Measure	808	809	(
I-outcome-Measure	809	813	LVEF
I-outcome-Measure	813	814	)
O	815	825	absolutely
O	826	827	≥
O	827	829	10
O	829	830	%
O	831	835	from
O	836	839	the
O	840	848	baseline
O	849	852	and
O	853	866	concomitantly
O	867	868	<
O	868	870	50
O	870	871	%
O	872	874	at
O	875	876	6
O	876	877	-
O	877	882	month
O	882	883	.

O	884	893	Composite
O	894	896	of
O	897	900	all
O	900	901	-
O	901	906	cause
O	907	912	death
O	912	913	,
O	914	919	heart
O	920	927	failure
O	928	931	and
O	932	943	readmission
O	944	948	were
O	949	957	compared
O	957	958	.

O	959	962	The
B-outcome	963	970	primary
I-outcome	971	978	outcome
O	979	982	was
O	983	986	not
O	987	1000	significantly
O	1001	1010	different
O	1011	1013	in
O	1014	1017	the
O	1018	1021	NAC
O	1022	1025	and
O	1026	1033	control
O	1034	1040	groups
O	1041	1042	{
B-iv-bin-abs	1042	1043	3
O	1043	1044	/
B-intervention-participants	1044	1046	47
O	1047	1048	(
B-iv-bin-percent	1048	1049	6
I-iv-bin-percent	1049	1050	.
I-iv-bin-percent	1050	1051	4
I-iv-bin-percent	1051	1052	%
O	1052	1053	)
O	1054	1056	vs
O	1056	1057	.
B-cv-bin-abs	1058	1059	1
O	1059	1060	/
B-control-participants	1060	1062	52
O	1063	1064	(
B-cv-bin-percent	1064	1065	1
I-cv-bin-percent	1065	1066	.
I-cv-bin-percent	1066	1067	9
I-cv-bin-percent	1067	1068	%
O	1068	1069	)
O	1069	1070	,
O	1071	1072	p
O	1072	1073	=
O	1073	1074	0
O	1074	1075	.
O	1075	1078	343
O	1078	1079	}
O	1079	1080	.

O	1081	1084	The
B-outcome	1085	1089	mean
I-outcome	1090	1094	LVEF
O	1095	1108	significantly
O	1109	1118	decreased
O	1119	1121	in
O	1122	1126	both
O	1127	1130	the
O	1131	1134	NAC
O	1135	1136	(
O	1136	1140	from
O	1141	1143	64
O	1143	1144	.
O	1144	1145	5
O	1146	1148	to
B-iv-cont-mean	1149	1151	60
I-iv-cont-mean	1151	1152	.
I-iv-cont-mean	1152	1153	8
I-iv-cont-mean	1153	1154	%
O	1154	1155	,
O	1156	1157	p
O	1157	1158	=
O	1158	1159	0
O	1159	1160	.
O	1160	1163	001
O	1163	1164	)
O	1165	1168	and
O	1169	1176	control
O	1177	1183	groups
O	1184	1185	(
O	1185	1189	from
O	1190	1192	64
O	1192	1193	.
O	1193	1194	1
O	1195	1197	to
B-cv-cont-mean	1198	1200	61
I-cv-cont-mean	1200	1201	.
I-cv-cont-mean	1201	1202	3
I-cv-cont-mean	1202	1203	%
O	1203	1204	,
O	1205	1206	p
O	1206	1207	<
O	1207	1208	0
O	1208	1209	.
O	1209	1212	001
O	1212	1213	)
O	1214	1219	after
O	1220	1223	the
O	1224	1234	completion
O	1235	1237	of
O	1238	1243	whole
O	1244	1256	chemotherapy
O	1256	1257	.

O	1258	1261	The
B-outcome	1262	1266	mean
I-outcome	1267	1271	LVEF
I-outcome	1272	1278	change
O	1279	1282	did
O	1283	1286	not
O	1287	1293	differ
O	1294	1301	between
O	1302	1305	the
O	1306	1309	two
O	1310	1316	groups
O	1317	1318	(
B-iv-cont-mean	1318	1319	-
I-iv-cont-mean	1319	1320	3
I-iv-cont-mean	1320	1321	.
I-iv-cont-mean	1321	1323	64
I-iv-cont-mean	1323	1324	%
O	1325	1327	in
O	1328	1331	NAC
O	1332	1334	vs
O	1334	1335	.
B-cv-cont-mean	1336	1337	-
I-cv-cont-mean	1337	1338	2
I-cv-cont-mean	1338	1339	.
I-cv-cont-mean	1339	1341	78
I-cv-cont-mean	1341	1342	%
O	1343	1345	in
O	1346	1353	control
O	1354	1359	group
O	1359	1360	,
O	1361	1362	p
O	1362	1363	=
O	1363	1364	0
O	1364	1365	.
O	1365	1368	502
O	1368	1369	)
O	1369	1370	.

B-outcome	1371	1375	Left
I-outcome	1376	1387	ventricular
I-outcome	1388	1389	(
I-outcome	1389	1391	LV
I-outcome	1391	1392	)
I-outcome	1393	1396	end
I-outcome	1397	1405	systolic
I-outcome	1406	1415	dimension
O	1416	1425	increased
O	1426	1430	with
O	1431	1437	higher
O	1438	1443	trend
O	1444	1446	in
O	1447	1450	NAC
O	1451	1453	by
B-iv-cont-mean	1454	1455	3
I-iv-cont-mean	1455	1456	.
I-iv-cont-mean	1456	1458	08
O	1458	1459	±
B-iv-cont-sd	1459	1460	4
I-iv-cont-sd	1460	1461	.
I-iv-cont-sd	1461	1463	56
I-iv-cont-sd	1464	1466	mm
O	1467	1469	as
O	1470	1478	compared
O	1479	1483	with
B-cv-cont-mean	1484	1485	1
I-cv-cont-mean	1485	1486	.
I-cv-cont-mean	1486	1488	47
O	1488	1489	±
B-cv-cont-sd	1489	1490	1
I-cv-cont-sd	1490	1491	.
I-cv-cont-sd	1491	1493	83
I-cv-cont-sd	1494	1496	mm
O	1497	1499	in
O	1500	1503	the
O	1504	1511	control
O	1512	1517	group
O	1518	1519	(
O	1519	1520	p
O	1520	1521	=
O	1521	1522	0
O	1522	1523	.
O	1523	1526	064
O	1526	1527	)
O	1527	1528	.

B-outcome	1529	1531	LV
I-outcome	1532	1535	end
I-outcome	1536	1545	diastolic
I-outcome	1546	1555	dimension
O	1556	1559	did
O	1560	1563	not
O	1564	1570	change
O	1571	1573	in
O	1574	1578	each
O	1579	1584	group
O	1585	1588	and
O	1589	1595	change
O	1596	1600	does
O	1601	1604	not
O	1605	1611	differ
O	1612	1614	in
O	1615	1619	both
O	1619	1620	.

B-outcome	1621	1625	Peak
I-outcome	1626	1627	E
O	1627	1628	,
B-outcome	1629	1630	A
I-outcome	1631	1634	and
I-outcome	1635	1636	E
I-outcome	1636	1637	/
I-outcome	1637	1638	A
I-outcome	1639	1644	ratio
I-outcome	1645	1651	change
O	1652	1655	and
B-outcome	1656	1663	cardiac
I-outcome	1664	1671	enzymes
O	1672	1676	were
O	1677	1687	comparable
O	1688	1690	in
O	1691	1694	two
O	1695	1701	groups
O	1701	1702	.

B-outcome	1703	1713	Cumulative
I-outcome	1714	1716	12
I-outcome	1716	1717	-
I-outcome	1717	1722	month
I-outcome	1723	1728	event
I-outcome	1729	1733	rate
O	1734	1737	was
B-iv-bin-percent	1738	1739	6
I-iv-bin-percent	1739	1740	%
O	1741	1744	and
B-cv-bin-percent	1745	1746	3
I-cv-bin-percent	1746	1747	.
I-cv-bin-percent	1747	1748	8
I-cv-bin-percent	1748	1749	%
O	1750	1752	in
O	1753	1756	the
O	1757	1760	NAC
O	1761	1766	group
O	1767	1770	and
O	1771	1774	the
O	1775	1782	control
O	1783	1788	group
O	1788	1789	,
O	1790	1802	respectively
O	1802	1803	,
O	1804	1808	with
O	1809	1811	no
O	1812	1822	difference
O	1823	1824	(
O	1824	1825	p
O	1825	1826	=
O	1826	1827	0
O	1827	1828	.
O	1828	1831	672
O	1831	1832	)
O	1832	1833	.

O	1834	1836	We
O	1837	1843	cannot
O	1844	1849	prove
O	1850	1854	that
O	1855	1858	NAC
O	1859	1867	prevents
O	1868	1881	anthracycline
O	1881	1882	-
O	1882	1889	induced
O	1890	1904	cardiomyopathy
O	1904	1905	.
